Coincidentally in the April 9 Neurology, Pasinetti, with Paul Aisen, now at Georgetown University Medical Center, Washington, DC, reported results of a small, randomized trial to test the feasibility of using the COX-2 inhibitor nimesulide as a chronic treatment in Alzheimer's patients.
Of the 40 volunteers, 21 took 100mg nimesulide twice daily, 19 received placebo. All underwent cognitive tests at trial onset and after a double-blind 12-week phase. There was no significant change in cognitive ability in either group.
All patients were offered to take nimesulide for a further 12 weeks. Thirty-six patients completed this open stage of the trial. Again, there were no significant differences in cognitive ability between the two groups after 24 weeks. Twenty-four patients continued the trial for an additional 12-month period, and eight patients were followed for two years.
Five patients developed nimesulide-related liver problems, including elevated transaminase activity. Some patients developed rash, constipation, or abdominal discomfort.—Tom Fagan
No Available References
No Available Further Reading
- Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology. 2002 Apr 9;58(7):1050-4. PubMed.